Flag of the European Union EU Clinical Trials Register Help

Clinical trials for roche OR chugai OR genentech

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,190 result(s) found for: roche OR chugai OR genentech. Displaying page 152 of 160.
    «« First « Previous 148  149  150  151  152  153  154  155  156  Next» Last»»
    EudraCT Number: 2018-001780-23 Sponsor Protocol Number: BTZ116577 Start Date*: 2019-12-04
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Unc...
    Medical condition: Uncomplicated Urogenital Gonorrhea
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002981-15 Sponsor Protocol Number: DanNORMS Start Date*: 2020-12-15
    Sponsor Name:Danish Multiple Sclerosis Center, Rigshospitalet
    Full Title: Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): A randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis.
    Medical condition: Multiple sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063400 Secondary progressive multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000060-22 Sponsor Protocol Number: 2020/0424/HP Start Date*: 2023-04-03
    Sponsor Name:CHU de Rouen
    Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti...
    Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000273-81 Sponsor Protocol Number: UC-GIG-2203 Start Date*: 2022-09-13
    Sponsor Name:UNICANCER
    Full Title: Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurre...
    Medical condition: Patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent or metastatic, ineligible for triplet chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001347-31 Sponsor Protocol Number: RF-2016-02361887 Start Date*: 2018-07-30
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Anti-nerve reactivity as predictor of response to immune therapy in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A proof of concept study with rituximab in patie...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10072650 CIDP LLT
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004666-26 Sponsor Protocol Number: 2015/208/HP Start Date*: 2017-07-19
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid
    Medical condition: severe forms of mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000627-53 Sponsor Protocol Number: P150922 Start Date*: 2016-11-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: MAINtenance of remission with RITuximab versus azathioprine for patients with newly-diagnosed or relapsing Eosinophilic Granulomatosis with polyangiitis. A prospective, randomized, controlled, doub...
    Medical condition: Patients with newly diagnosed or relapsing EGPA, after achievement of remission.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10009164 Churg Strauss syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004718-32 Sponsor Protocol Number: NL72607.041.20 Start Date*: 2020-10-09
    Sponsor Name:UMC Utrecht
    Full Title: Upfront autologous hematopoietic stem cell transplantation versus immunosuppressive medication in early diffuse cutaneous systemic sclerosis: an international multicentre, open-label, randomized co...
    Medical condition: Diffuse cutaneous systemic sclerosis according to the ACR/EULAR criteria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001663-39 Sponsor Protocol Number: D4190C00022 Start Date*: 2015-11-27
    Sponsor Name:MedImmune
    Full Title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000111-84 Sponsor Protocol Number: ACE-LY-003 Start Date*: 2020-02-04
    Sponsor Name:ACERTA PHARMA BV
    Full Title: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
    Medical condition: B-cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012813-22 Sponsor Protocol Number: PRODIGE 14 - ACCORD 21/0905 Start Date*: 2010-08-20
    Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
    Full Title: Essai de phase II, randomisé multicentrique, évaluant le meilleur protocole de chimiothérapie associée à une thérapie ciblée choisie selon le statut KRAS dans les métastases hépatiques initialement...
    Medical condition: Cancer colorectal métastatique, première ligne de traitement, avec métastases hépatiques initialement non résécables.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055114 Colon cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-003936-10 Sponsor Protocol Number: D8220C00027 Start Date*: 2022-06-28
    Sponsor Name:AstraZeneca AB
    Full Title: MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia o...
    Medical condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000862-49 Sponsor Protocol Number: RG_15-011 Start Date*: 2016-08-22
    Sponsor Name:The University of Birmingham
    Full Title: Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer?
    Medical condition: Early rectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) GB (GB - no longer in EU/EEA) DK (Completed) SE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000605-84 Sponsor Protocol Number: XPORT-DLBCL-030 Start Date*: 2020-09-16
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL...
    Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000758-39 Sponsor Protocol Number: PREBEN Start Date*: 2015-12-13
    Sponsor Name:Department of Hematology, Aarhus University Hospital
    Full Title: A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell pheno...
    Medical condition: Relapse of aggressive non-Hodgkin lymphoma of B and T-cell phenotype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) SE (Ongoing) FI (Prematurely Ended) NO (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005061-31 Sponsor Protocol Number: GATA Start Date*: 2017-10-07
    Sponsor Name:LYSARC
    Full Title: A PHASE II TRIAL EVALUATING COMBINATION OF ATEZOLIZUMAB, WITH VENETOCLAX AND OBINUTUZUMAB FOR RELAPSED/REFRACTORY LYMPHOMAS
    Medical condition: - relapsed/refractory follicular lymphoma (FL) patients - relapsed/refractory aggressive (DLBCL) lymphoma patients - relapsed/refractory other indolent lymphoma patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016906 Follicle centre lymphoma, follicular grade I, II, III refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015824 Extranodal marginal zone B-cell lymphoma (MALT type) refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003912 B-cell small lymphocytic lymphoma refractory PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004699-21 Sponsor Protocol Number: CP-MGAH22-06 Start Date*: 2020-10-12
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positiv...
    Medical condition: Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER2 positive gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003704-39 Sponsor Protocol Number: NEAT22/SSAT060 Start Date*: 2014-04-01
    Sponsor Name:St Stephen's AIDS Trust [...]
    1. St Stephen's AIDS Trust
    2. NEAT-ID
    Full Title: An open label study examining the efficacy and cardiovascular risk of immediate versus deferred switch from a boosted PI to dolutegravir (DTG) in HIV infected patients with stable virological suppr...
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003120-36 Sponsor Protocol Number: IMC-C103C-101 Start Date*: 2020-01-03
    Sponsor Name:Immunocore Limited
    Full Title: A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer
    Medical condition: Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10062006 HLA marker study PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030155 Oesophageal carcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017770 Gastric carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005127-29 Sponsor Protocol Number: TAX_GMA_302 Start Date*: 2001-05-21
    Sponsor Name:SANOFI-AVENTIS
    Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI...
    Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 148  149  150  151  152  153  154  155  156  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 05:34:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA